C4 Therapeutics (NASDAQ:CCCC – Get Free Report) is projected to announce its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.44) per share and revenue of $4.43 million for the quarter.
C4 Therapeutics Price Performance
Shares of CCCC opened at $2.79 on Wednesday. C4 Therapeutics has a one year low of $2.69 and a one year high of $11.88. The stock has a market cap of $196.94 million, a price-to-earnings ratio of -1.64 and a beta of 2.95. The company has a 50-day moving average of $3.59 and a two-hundred day moving average of $4.86.
Analysts Set New Price Targets
Several research firms have weighed in on CCCC. Wells Fargo & Company upgraded C4 Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $8.00 to $12.00 in a report on Thursday, December 19th. UBS Group upgraded C4 Therapeutics to a “hold” rating in a research report on Friday, February 14th. Finally, Stephens initiated coverage on shares of C4 Therapeutics in a research report on Monday, November 18th. They issued an “equal weight” rating and a $4.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, C4 Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.60.
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Read More
- Five stocks we like better than C4 Therapeutics
- Trading Halts Explained
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Dividend Capture Strategy: What You Need to Know
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Stock Sentiment Analysis: How it Works
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
